Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 46.5 Cr.
- Current Price ₹ 49.5
- High / Low ₹ 68.4 / 40.5
- Stock P/E 27.5
- Book Value ₹ 16.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 11.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 65.2 days to 39.2 days
Cons
- Stock is trading at 3.10 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2020 1m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1.43 | 6.07 | 26.76 | 28.70 | 51.31 | 60.16 | |
| 1.05 | 5.61 | 25.68 | 27.92 | 49.54 | 57.32 | |
| Operating Profit | 0.38 | 0.46 | 1.08 | 0.78 | 1.77 | 2.84 |
| OPM % | 26.57% | 7.58% | 4.04% | 2.72% | 3.45% | 4.72% |
| 0.00 | 0.00 | 0.02 | 0.27 | 0.13 | 0.10 | |
| Interest | 0.05 | 0.18 | 0.48 | 0.34 | 0.21 | 0.10 |
| Depreciation | 0.02 | 0.12 | 0.28 | 0.25 | 0.21 | 0.41 |
| Profit before tax | 0.31 | 0.16 | 0.34 | 0.46 | 1.48 | 2.43 |
| Tax % | 25.81% | 6.25% | -26.47% | 34.78% | 24.32% | 30.45% |
| 0.23 | 0.15 | 0.42 | 0.29 | 1.11 | 1.69 | |
| EPS in Rs | 0.38 | 0.22 | 0.46 | 0.32 | 1.18 | 1.80 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 58% |
| TTM: | 59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 43% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 |
| Reserves | 0.23 | 1.44 | 6.49 | 6.78 | 8.64 | 5.63 |
| 5.88 | 5.46 | 4.38 | 3.21 | 0.32 | 0.00 | |
| 5.44 | 5.45 | 7.95 | 7.33 | 9.84 | 15.90 | |
| Total Liabilities | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 |
| 1.15 | 1.07 | 0.94 | 0.83 | 1.48 | 2.29 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 |
| Investments | 0.00 | 0.06 | 2.93 | 2.84 | 4.70 | 4.70 |
| 13.40 | 14.56 | 19.49 | 18.17 | 17.30 | 23.90 | |
| Total Assets | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 0.40 | 1.38 | -0.32 | 1.09 | 3.13 | 2.71 | |
| 0.00 | -0.70 | -4.58 | 0.46 | -0.88 | -1.23 | |
| -0.24 | -0.06 | 4.27 | -1.52 | -2.18 | -0.42 | |
| Net Cash Flow | 0.17 | 0.62 | -0.63 | 0.03 | 0.07 | 1.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 2,141.50 | 430.54 | 124.26 | 111.66 | 71.78 | 102.84 |
| Inventory Days | 1,690.75 | 369.26 | 103.22 | 89.87 | 39.99 | 32.83 |
| Days Payable | 2,156.44 | 434.08 | 130.02 | 99.69 | 67.10 | 93.80 |
| Cash Conversion Cycle | 1,675.81 | 365.73 | 97.45 | 101.84 | 44.67 | 41.87 |
| Working Capital Days | 1,556.99 | 439.56 | 117.71 | 107.72 | 48.59 | 39.19 |
| ROCE % | 6.55% | 5.34% | 11.56% | 17.64% |
Documents
Announcements
-
Clarification - Financial Results
21 June 2025 - Exchange has sought clarification from Walpar Nutritions Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Outcome of Board Meeting
15 May 2025 - Audited standalone and consolidated financial results for FY ended March 31, 2025 approved with unmodified audit opinion.
-
Integrated Filing- Financial
15 May 2025 - Audited standalone and consolidated financial results for FY ended March 31, 2025 with unmodified auditor opinion.
-
Updates
15 May 2025 - Approved audited financial results for FY25; appointed secretarial and internal auditors; unmodified audit opinion.
-
Outcome of Board Meeting
15 May 2025 - Audited financial results for FY 2024-25 approved; unmodified audit opinion; new secretarial and internal auditors appointed.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products